The Alzheimer’s Disease and Memory Disorders Center (ADMDC) conducts clinical trials that give participants access to the latest, most comprehensive diagnostic and treatment options available.
There is currently no cure for Alzheimer's disease, but scientists are constantly working to advance research through clinical studies with the help of human volunteers. Without these volunteers, there can be no better treatments, prevention, or cure for Alzheimer's.
Both people with the disease and healthy volunteers are needed for Alzheimer's-related clinical trials. Before joining a clinical trial, an individual must qualify for the study. All clinical trials have guidelines about who can participate. These criteria are based on factors such as age, gender, the type and stage of the disease, previous treatment history, and other medical conditions.
Your information will go directly to our research team who will contact you about upcoming clinical trials.
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease (BALANCE-AAD-1)
Age: 60 to 90 years of age, agitation due to Alzheimer’s Disease diagnosis
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 2)
Age: 65 to 85 years of age, Mild to Moderate Alzheimer’s Disease diagnosis
Metformin in Alzheimer's Dementia Prevention (MAP)
Donanemab in Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 2)
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer’s Disease (MTAE)
Long-Term Nicotine Treatment of Mild Cognitive Impairment (NIC)
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
The research focus of this laboratory is to characterize the contribution of CNVs to the genetic architecture of AD to develop genetic biomarkers for risk stratification.
For Consultations, Referrals, and Information:
Alzheimer's Disease and Memory Disorders Center
Clinic Locations:
1001 Main Street, Fl 4
Buffalo, NY 14203
716-829-5056
5851 Main Street
Williamsville, NY 14221
716-829-5056